A review of patient self-report tools for chemotherapy-induced nausea and vomiting
Tóm tắt
The assessment of chemotherapy-induced nausea, vomiting and retching (CINVR) is important and to date no review has comprehensively assessed available patient self-report tools. The aim was to undertake a review of their utility, content and psychometric properties. One thousand three hundred and forty-seven citations were identified by electronic and hand searches resulting in 24 non-duplicate abstracts, 15 articles for analysis, and six articles, which fitted the inclusion criteria. E-mail investigations discovered a further scale, resulting in seven measures. The review highlighted the strengths and weaknesses of current tools. The multiple domains, phases and aspects of CINVR signify that the assessment tools varied markedly. The diverse requirements of research and clinicians also contribute to the variation. There was a notable disparity in the quality of scales and paucity in terms of their development and psychometric evaluation. We found that several self-assessment scales currently perceived as well-validated tools have problems in terms of their validity, reliability and appropriateness. The constituents of a scale relevant for both clinical and research use were assessed and it was recommended that a modular tool focusing on two domains (nausea and vomiting); two phases (acute and delayed); measuring the aspects of occurrence, frequency, intensity alongside duration and functional interference; and antiemetic use and adverse events should be developed. Based on these recommendations, further research into an appropriate scale would minimise conceptual confusion, increase clinicians’ understanding and control of CINVR, decrease patient distress and could have equal utility in both a clinical and a research setting.
Tài liệu tham khảo
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KC, Sullivan M, Takeda D (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
Alves-Guerreiro J, Lowe-Strong AS, Walsh DM, Lopes BC, Costa R, Rosado R, Monforte E, Rolo T, Projecto J, Ferreira M (2003) Development of a Portuguese version of the Morrow Assessment of Nausea and Emesis (MANE) questionnaire: moving physical therapy forward [abstract]. 14th International World Confederation for Physical Therapy Congress
Bergkvist K, Wengström Y (2006) Symptom experience during chemotherapy treatment—with focus on nausea and vomiting. Eur J Oncol Nurs 10:21–29
Carnrike CLM Jr, Carey MP (1990) Assessing nausea and vomiting in adult chemotherapy patients: review and recommendations. Ann Behav Med 12:79–85
Carnrike CLM, Brantley PJ, Bruce B, Faruqui S, Gresham FM, Buss RR, Cocke TB (1988) Test–restest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy- related nausea and vomiting. J Psychopathol Behav Assess 10:107–116
Chou F-H, Avant KC, Kuo S-H, Cheng HF (2005) Assessing the psychometric and language equivalency of the Chinese versions of the index of nausea, vomiting and retching, and the prenatal self-evaluation questionnaire. Kaohsiung J Med Sci 21:314–321
Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J (1996) Efficacy and tolerability or oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphomide-based chemotherapy and maintenance of health-related quality of life. Clin Ther 18:778–788
Coates AS, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox R, Tattersall M (1983) On the receiving end: patient perception of the side effects of chemotherapy. Eur J Cancer Clin Oncol 19:203–208
de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061
Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35–41
DeGroot T, Einhorn L, Brames J, Roth BJ, Dreicer R, Nichols C, Bubalo J (2006) Multiple-day Palonosetron antiemetic regimen is safe and effective for preventing chemotherapy-induced nausea and vomiting in patients receiving 5-day Cisplatin for testicular cancer. Presented at Chicago Supportive Oncology Conference Sept 27–30
Dibble SL, Chapman J, Mack KA, Shih A (2000) Acupressure for nausea: results of a pilot study. Oncol Nurs Forum 27:41–47
Dibble SL, Israel J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30:40–47
Farley PA, Dempsey CL, Shillington AA, Kulis-Robitaille C, Colgan K, Bernstein G (1997) Patients’ self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health-Syst Pharm 54:2478–2482
Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient- reported symptoms form the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490
Fu MR, Rhodes V, Xu B (2002) The Chinese translation of the index of nausea, vomiting and retching. Cancer Nurs 25:134–140
Glaus A, Knipping C, Morant R, Bohme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Husler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715
Gift AG, Jablonski A, Stommel M, Given WC (2004) Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum 31:203–209
Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end v: patient perceptions of the side effects of chemotherapy in 1993. Ann Oncol 7:189–195
Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268
Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221–227
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21:4112–4119
Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro AM, Gandara D, Lindley C (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109
Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5 hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 1:2880–2886
Hickock JT, Roscoe JA, Morrow GR, Stern RM, Yang B, Flynn PJ, Kirshner HE, Rosenbluth R (1999) Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. Cancer 86:64–71
Honea N, Breant J, Beck SL (2007) Treatment related symptom cluster. Semin Oncol Nurs 23:142–151
Huschka M, Burger K (2006) Does QOL provide the same information as toxicity data? Curr Probl Cancer 30:244–254
Kim YJ, Kim JY, Choi IR, Kim MW, Rhodes V (2000) The index of nausea, vomiting and retching (Korean Translation). Korean Acad Adult Nurs 12:278–285
Kobayashi K, Ishihara Y, Nukariya N, Niitani H, Furue H, Joint Research Group for Tropisetron Double-Blind Comparative Study (1999) Effects of an antiemetic drug (Tropisetron) on a quality of life during chemotherapy: use of a diary-type questionnaire and application of summary measures for assessment in a randomized, multicentre study. Respirology 4:229–238
Lebeau B, Depierre A, Giovanni M, Riviere A, Kaluzinski L, Votan B, Hédouin M, d’Allens H (1997) The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 8:887–892
Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340
Lo LH, Hayman LL (1999) Parents associated with children in measuring acute and delayed nausea and vomiting. Nurs Health Sci 1:155–161
Martin A, Pearson J, Cai B, Elmer M, Horgan K, Lindley CM (2000) Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res 9:18
Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522–527
Martin AR, Carides AD, Pearson JD, Elmer M, Schmidt C, Cai B, Grunberg SM (2003) Functional relevance of antiemetic control—experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395–1401
Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Psychometric properties of a quality of life questionnaire. Cancer 98:645–655
Miller M, Kearney N (2004) Chemotherapy-related nausea and vomiting- past reflections, present practice and future management. Eur J Cancer Care 13:71–81
Molassiotis A, Börjeson S (2006) Nausea and vomiting. In: Kearney N, Richardson A (eds) Nursing patients with cancer: principles and practice. Edinburgh, Elsevier Churchill Livingstone, pp 415–43
Molassiotis A, Saunders M, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-induced nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201–208
Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symptom Manage 34:148–159
Molassiotis A, Helin AM, Dabbour R, Hummerston S (2007) The effects of P6 acupressure in the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients. Comp Ther Med 15:3–7
Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS (2002) The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. A randomised controlled trial. Support Care Cancer 10:237–246
Morrow G (1984) Methodology in behavioural and psychosocial cancer research. The assessment nausea and vomiting. Past problems, current issues, and suggestions for future research. Cancer 53(Suppl):2267–2278
Morrow G (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer 66(Suppl XIX):S72–S74
Mullin SM, Fletcher DM, Tyler LS (1998) Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients. Am J Health-Syst Pharm 55:1903–1906
Olver IN, Matthews JP, Bishop JF, Smith RA (1994) The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 30:1223–1227
Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608–616
Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307–313
Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15:116–123
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Guoguang JM, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results form a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3097
Presant CA (1984) Quality of life in cancer patients. Who measures what? Am J Clin Oncol 7:571–573
Rhodes VA, Watson PM, Johnson MH (1984) Development of reliable and valid measures of nausea and vomiting. Cancer Nurs 7:33–41
Rhodes VA, McDaniel RW (1997) Measuring nausea, vomiting and retching. In: Frank-Stromborg M, Olsen SJ (eds) Instruments for clinical health-care research,. 2nd edn. Jones & Bartlett, Boston, pp 509–518
Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and retching: a new format of the lndex of nausea and vomiting. Oncol Nurs Forum 26:889–894
Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113–121
Sarna L (1998) Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum 25:1041–1048
Satou A, Yamazaki T, Nukariya N, Nakamachi M, Shimada K, Matsukawa M, Kurihara M (2002) Development of a Japanese version of the FLIE. Japanese Journal of Cancer and Chemotherapy 28:281–291
Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 2:472–483
Schwartzberg L (2006) Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 4:3–8
Smith HS (2005) A receptor-based paradigm of nausea and vomiting. J Cancer Pain Symptom Pall 1:11–23
Streiner DL (1993) A checklist for evaluating the usefulness of rating scales. Can J Psychiatry 38:140–148
Streiner DL, Norman GR (1995) Health measurement scales: a practical guide to their development and use, 2nd edn. Oxford University Press, New York
Sykes AJ, Kiltie AE, Stewart AL (1997) Ondasetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 5:500–503